Management of Typhoid Fever in Children

First-Line Antibiotic Treatment

The American Academy of Pediatrics recommends azithromycin 20 mg/kg/day (maximum 1g/day) orally for 7 days as the preferred first-line treatment for typhoid fever in children, particularly given the widespread fluoroquinolone resistance exceeding 70% in most endemic regions 1, 2
Azithromycin achieves a 94% cure rate in children with significantly lower clinical failure risk (OR 0.48) compared to fluoroquinolones 1, 2
Azithromycin dramatically reduces relapse rates (OR 0.09) compared to ceftriaxone, with zero relapses documented in pediatric studies versus 4-6 relapses in ceftriaxone groups 1

For severe cases requiring hospitalization, the Infectious Diseases Society of America recommends ceftriaxone 50-80 mg/kg/day (maximum 2g/day) IV/IM for 5-7 days 1, 2
For infants under 3 months, the American Academy of Pediatrics recommends third-generation cephalosporin (ceftriaxone) due to age-specific considerations 2, 3

The Centers for Disease Control and Prevention recommends obtaining 2-3 blood cultures before initiating antibiotics to maximize detection given low-magnitude bacteremia 2, 3
Blood cultures have the highest yield within the first week of symptom onset 1

The World Health Organization recommends that fever should clear within 4-5 days of appropriate therapy 1, 2
If no clinical response by day 5, consider antibiotic resistance or alternative diagnosis 1

The American Academy of Pediatrics recommends ensuring adequate hydration with oral rehydration solution or IV fluids as dehydration increases the risk of life-threatening complications, especially in infants 3
Continue breastfeeding throughout illness if the infant is breastfed 3

The Centers for Disease Control and Prevention recommends two typhoid vaccines licensed in the United States, but not routinely recommended 4
Ty21a oral vaccine: one capsule on alternate days for a total of 4 capsules (children ≥6 years), with boosting every 5 years 5, 4
Vi-polysaccharide parenteral vaccine: single dose (children ≥2 years), with boosting every 2 years 5, 4

The World Health Organization recommends considering local resistance patterns when selecting empiric therapy, as these vary geographically and change over time 1, 2
South Asia has >70% fluoroquinolone resistance, up to 96% in some areas 1, 2